Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 11

  • 591 clinical trials
  • 223 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease64Bladder cancer55Transitional cell carcinoma47Renal cell carcinoma42Bladder transitional cell carcinoma34IgA nephropathy24Acute kidney injury21Non-small cell lung cancer19Urinary tract infection19Lupus nephritis18Clear cell renal cell carcinoma17Paroxysmal nocturnal haemoglobinuria17Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

591 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

591 clinical trials

Clear cell renal cell carcinoma

Recruiting

Study on the Effectiveness of Early PSMA-PET Scans with Gozetotide in Patients with Metastatic Renal Cancer Undergoing Standard Immunotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Cliniques Universitaires Saint-Luc

Metastatic renal cell carcinoma

Recruiting

Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Congenital cystic kidney disease

Recruiting

Study on the Safety of Rotigotine for Patients with Autosomal Dominant Polycystic Kidney Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Rotigotine
  • Sponsor:Centre Hospitalier Universitaire Rouen

Septic shock+1

Recruiting

Study on the Effect of Human Serum Albumin in Critically Ill Patients with Septic Shock at High Risk of Acute Kidney Injury

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Fundacio Parc Tauli

Bladder transitional cell carcinoma

Recruiting

Study on the Effectiveness and Safety of Mitomycin C with Electric Current for Treating Non-Muscle Invasive Bladder Cancer in Patients, Compared to Standard Immunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Presurgy S.L.

Paroxysmal nocturnal haemoglobinuria

Recruiting

Study of Danicopan with Ravulizumab or Eculizumab for Children with Paroxysmal Nocturnal Hemoglobinuria and Extravascular Hemolysis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

IgA nephropathy

Recruiting

Study on the Effectiveness and Safety of Budesonide and Prednisone for Children with Primary IgA Nephropathy

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:Medical University Of Warsaw

Bladder cancer

Recruiting

Study on Cisplatin, Nab-paclitaxel, and Nivolumab with Radiotherapy for Patients with Non-Metastatic Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Glomerulonephritis minimal lesion+1

Recruiting

Study on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Endometrial cancer+13

Recruiting

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Bladder transitional cell carcinoma

Recruiting

Study on Mitomycin and BCG for Patients with Recurrent Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Aarhus University

Adenocarcinoma gastric+13

Recruiting

Study of JK06 for Patients with Advanced or Metastatic Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:JK06
  • Sponsor:Salubris Biotherapeutics Inc.

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab54 clinical trialsNivolumab36 clinical trialsDapagliflozin25 clinical trialsMycophenolate Mofetil24 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.